Orionis Biosciences

Orionis Biosciences is a clinical-stage life sciences company based in Waltham, Massachusetts, with a research facility in Ghent, Belgium.

Founded in 2015, the company focuses on discovering and engineering conditionally active drug modalities that target disease-driving processes and activate immune responses. Orionis specializes in translational drug discovery, utilizing innovative technologies to enhance drug potency and precision for life-threatening diseases, particularly in cancer and immunology. The company operates two proprietary platforms: A-KineTM, which creates conditionally active immunotherapies with high cell target selectivity, and Allo-GlueTM, a small-molecule platform for molecular glue drug discovery. Orionis has a robust drug discovery pipeline, including two cancer immunotherapy drugs in clinical trials and several advanced preclinical programs. The company collaborates with strategic pharmaceutical partners like Novartis and Genentech/Roche, while also targeting patients with advanced diseases through its internal clinical programs. Orionis has raised significant funding and continues to advance its mission in the life sciences sector.